Drug Trial Radar · NCT05602675
A Drug Interaction Study of LY3871801 in Healthy Participants
Last checked: Nov 19, 2026Latest source record: Apr 18, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
39
Actual
Start
Nov 2, 2022
Primary completion
Mar 29, 2023
Study completion Mar 29, 2023
Sponsor
- Lead sponsor
- Eli Lilly and CompanyEli Lilly (LLY)
- Sponsor type
- Industry
- First posted
- Nov 2, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Basic science
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The main purpose of this study is to determine the effect of LY3871801 when administered orally on the levels of methotrexate (part 1), drug cocktail (warfarin, dextromethorphan, and midazolam) and repaglinide (part 2) in the blood stream when administered orally in healthy participants. The information about any adverse effects experienced will be collected and the tolerability of LY3871801 will also be evaluated. The study may last up to approximately 25 days for each participant.
Conditions
- Healthy
Interventions
LY3871801Drug
Administered orally.
MethotrexateDrug
Administered orally.
WarfarinDrug
Administered orally.
DextromethorphanDrug
Administered orally.
MidazolamDrug
Administered orally.
RepaglinideDrug
Administered orally.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Part 1: Pharmacokinetics (PK): Maximum Concentration (Cmax) of MethotrexateTime frame: Predose up to 48 hours postdose
- Part 1: PK: Area Under the Plasma Concentration Versus Time Curve From Zero to Infinity (AUC[0-∞]) of MethotrexateTime frame: Predose up to 48 hours postdose
- Part 2: PK: Cmax of MidazolamTime frame: Predose up to 24 hours postdose
- Part 2: PK: AUC[0-∞] of MidazolamTime frame: Predose up to 24 hours postdose
- Part 2: PK: Cmax of S-warfarinTime frame: Predose up to 96 hours postdose
- Part 2: PK: AUC[0-∞] of S-warfarinTime frame: Predose up to 96 hours postdose
- Part 2: PK: Cmax of DextromethorphanTime frame: Predose up to 72 hours postdose
- Part 2: PK: AUC[0-∞] of DextromethorphanTime frame: Predose up to 72 hours postdose
- Part 2: PK: Cmax of RepaglinideTime frame: Predose up to 24 hours postdose
- Part 2: PK: AUC[0-∞] of RepaglinideTime frame: Predose up to 24 hours postdose
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Covance Dallas
Dallas, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.